Abstract

BackgroundThe active substance of Remicade is infliximab. It is a chimeric human-murine monoclonal antibody directed against tumour necrosis factor α (TNFα), manufactured from a recombinant cell line. Remicade is presented...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call